BridgeBio Pharma Inc. [NASDAQ: BBIO] loss -6.25% or -3.63 points to close at $54.49 with a heavy trading volume of 1438346 shares. The company report on April 7, 2021 that BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4).
BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced that on April 5, 2021, the compensation committee of BridgeBio’s board of directors granted 19 new employees restricted stock units for an aggregate of 32,691 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019.
It opened the trading session at $57.54, the shares rose to $58.08 and dropped to $54.015, the range by which the price of stock traded the whole day. The daily chart for BBIO points out that the company has recorded 35.18% gains over the past six months. However, it is still -115.89% lower than its most recent low trading price.
If we look at the average trading volume of 1.05M shares, BBIO reached to a volume of 1438346 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about BridgeBio Pharma Inc. [BBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BBIO shares is $84.22 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BBIO stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for BridgeBio Pharma Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 22, 2021. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on February 22, 2021, representing the official price target for BridgeBio Pharma Inc. stock. Previously, the target price had yet another raise to $83, while Goldman analysts kept a Buy rating on BBIO stock. On January 11, 2021, analysts increased their price target for BBIO shares from 64 to 87.
The Average True Range (ATR) for BridgeBio Pharma Inc. is set at 3.77, with the Price to Sales ratio for BBIO stock in the period of the last 12 months amounting to 1055.78. The Price to Book ratio for the last quarter was 111.20, with the Price to Cash per share for the same quarter was set at 3.82.
Trading performance analysis for BBIO stock
BridgeBio Pharma Inc. [BBIO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.20. With this latest performance, BBIO shares dropped by -21.84% in over the last four-week period, additionally plugging by 35.18% over the last 6 months – not to mention a rise of 102.34% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BBIO stock in for the last two-week period is set at 37.84, with the RSI for the last a single of trading hit 34.11, and the three-weeks RSI is set at 40.72 for BridgeBio Pharma Inc. [BBIO]. The present Moving Average for the last 50 days of trading for this stock 64.29, while it was recorded at 57.08 for the last single week of trading, and 48.01 for the last 200 days.
BridgeBio Pharma Inc. [BBIO]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and BridgeBio Pharma Inc. [BBIO] shares currently have an operating margin of -5751.99. BridgeBio Pharma Inc.’s Net Margin is presently recorded at -5439.74.
Return on Total Capital for BBIO is now -80.46, given the latest momentum, and Return on Invested Capital for the company is -85.58. Return on Equity for this stock declined to -192.44, with Return on Assets sitting at -67.21. When it comes to the capital structure of this company, BridgeBio Pharma Inc. [BBIO] has a Total Debt to Total Equity ratio set at 856.19. Additionally, BBIO Total Debt to Total Capital is recorded at 89.54, with Total Debt to Total Assets ending up at 70.47. Long-Term Debt to Equity for the company is recorded at 847.12, with the Long-Term Debt to Total Capital now at 88.59.
Reflecting on the efficiency of the workforce at the company, BridgeBio Pharma Inc. [BBIO] managed to generate an average of -$1,165,517 per employee.BridgeBio Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.70 and a Current Ratio set at 6.70.
BridgeBio Pharma Inc. [BBIO]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, BridgeBio Pharma Inc. posted -0.78/share EPS, while the average EPS was predicted by analysts to be reported at -0.67/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -16.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BBIO.
An analysis of insider ownership at BridgeBio Pharma Inc. [BBIO]
There are presently around $7,727 million, or 81.60% of BBIO stock, in the hands of institutional investors. The top three institutional holders of BBIO stocks are: KOHLBERG KRAVIS ROBERTS & CO. L.P. with ownership of 34,510,971, which is approximately 0% of the company’s market cap and around 6.00% of the total institutional ownership; VIKING GLOBAL INVESTORS LP, holding 26,620,991 shares of the stock with an approximate value of $1.45 billion in BBIO stocks shares; and BLACKROCK INC., currently with $512.12 million in BBIO stock with ownership of nearly 5.444% of the company’s market capitalization.
Positions in BridgeBio Pharma Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 138 institutional holders increased their position in BridgeBio Pharma Inc. [NASDAQ:BBIO] by around 12,409,768 shares. Additionally, 73 investors decreased positions by around 10,474,617 shares, while 18 investors held positions by with 118,921,037 shares. The mentioned changes placed institutional holdings at 141,805,422 shares, according to the latest SEC report filing. BBIO stock had 72 new institutional investments in for a total of 8,338,228 shares, while 20 institutional investors sold positions of 5,158,335 shares during the same period.